HKChina has begun construction on its first AI-powered personalized tumor vaccine production line, set to open in Beijing by October. The facility, developed by Likang Life Sciences, will focus on creating LK101, a vaccine that uses AI to analyze tumor DNA and identify genetic mutations driving cancer. The project is part of a broader trend in the pharmaceutical industry toward using artificial intelligence in drug development and healthcare. Experts note that while AI has significant potential to improve diagnostics and personalize treatments, its current adoption remains in early stages. The initiative highlights China's growing investment in advanced medical technologies.
Bias read (Center): The article presents information about a technological advancement in healthcare without overtly promoting or criticizing any political stance. It discusses the development of AI-driven medical technology, which is a scientific and economic issue rather than a politically charged topic. While the AI
